- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic migraine
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Galcanezumab – July 2019
Galcanezumab: Injection 120 mg in 1 mL single use pre-filled pen; Emgality®
Last updated
1 November 2019